Sucampo Pharma, Ltd., of Japan, a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), today announced that it has initiated dosing in a first-in-human clinical safety study of a proprietary prostone, SPL-017, as a potential treatment for peripheral arterial disease (PAD). The randomized, double-blind, placebo-controlled, single-center, single ascending dose study will evaluate the safety and pharmacokinetic profile of SPL-017. Complete news at...
Researchers in Germany are reporting an advance toward development of technology that could make life easier for millions of people allergic to plant pollen. It could underpin the first automated, real-time systems for identifying specific kinds of allergy-inducing plant pollen circulating in the air. Their study is in the current issue of ACS' Analytical Chemistry, a semi-monthly journal. Complete news at...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment